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ABSTRACT 23 
BACKGROUND AND OBJECTIVE: Porphyromonas gingivalis is a major pathogen 24 
involved in oral diseases such as periodontitis and peri-implantitis. Management of these 25 
diseases typically includes mechanical debridement of the colonized surfaces followed by 26 
application of antiseptics or antibiotics. Disadvantages associated with the use of antiseptics 27 
and the growing worldwide problem of antibiotic resistance have necessitated the search for 28 
alternative agents. In the current study, the antibacterial and antibiofilm properties of AM404, 29 
an active metabolite of paracetamol, were tested against P. gingivalis and other bacterial 30 
pathogens. 31 
MATERIALS AND METHODS: The activity of AM404 was tested against ten different 32 
bacteria, including both oral and non-oral human pathogens. The minimal inhibitory 33 
concentration (MIC) of AM404 was determined by measuring OD values. The minimum 34 
biofilm inhibitory concentration was detected by crystal violet staining. The activity of 35 
structural analogs of AM404 was tested by MIC determinations. The effect of AM404 on P. 36 
gingivalis biofilms formed on titanium disks as a model for dental implants was evaluated by 37 
colony forming unit (CFU) counting. Potential cytotoxicity of AM404 towards HEK-293 38 
(human embryonic kidney cells), HepG2 (human hepatoma cells), IEC-6 (rat intestinal cells) 39 
and Panc-1 cells (pancreatic cancer cells) was assessed by MTT assays. To get more insight in 40 
the mode of action of AM404, the fluorescent dyes N-phenyl-1-napthylamine (NPN) and 41 
SYTOX green were used to investigate outer and inner membrane damage of P. gingivalis 42 
induced by AM404, respectively.  43 
RESULTS: Of all tested pathogens, AM404 only inhibited growth and biofilm formation of 44 
P. gingivalis. Moreover, it showed potent activity against P. gingivalis biofilms formed on 45 
3 
 
titanium surfaces. A structure-activity analysis demonstrated that the unsaturated carbon chain 46 
is essential for its antibacterial activity. Importantly, AM404 was not toxic towards the tested 47 
mammalian cells up to concentrations approaching 4x the MIC. Membrane damage assays 48 
using fluorescent probes NPN and SYTOX green revealed that membrane permeabilization 49 
presumably is the primary antibacterial mode of action of AM404. 50 
CONCLUSION: Collectively, our results suggest that AM404 has the potential to be used for 51 
the development of new drugs specifically targeting P. gingivalis-related infections. 52 
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 57 
INTRODUCTION 58 
Porphyromonas gingivalis is a Gram-negative anaerobic bacterium identified as one of the 59 
major periodontal pathogens [1]. It exerts its pathogenic effects via a subset of virulence 60 
factors including fimbriae and the production of cysteine proteinases, hemaglutinins, and 61 
lipopolysaccharides [2]. In addition, pathogenicity is enhanced by its ability to form biofilms 62 
on both biotic and abiotic surfaces, yielding protection against environmental stress factors 63 
such as antibiotics and host defense mechanisms [3, 4].  64 
P. gingivalis is recognized as a major pathogen involved in chronic inflammatory diseases 65 
such as periodontitis and peri-implantitis, which result in the destruction of soft and hard 66 
tissues surrounding the teeth and dental implants, respectively [1, 5–7]. Recent studies have 67 
reported that the prevalence of periodontitis among US adults is as high as 46 % [8]. In 68 
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addition, the prevalence of peri-implantitis is estimated to be about 20 - 56 % for all implant 69 
patients, depending on the time frame under investigation [9, 10]. These numbers are expected 70 
to increase substantially with the expected aging of the population. 71 
Treatment of P. gingivalis-mediated diseases usually includes surface debridement procedures 72 
and the administration of anti-infective agents such as chlorhexidine or antibiotics [11–16]. 73 
However, side effects are associated with the use of chlorhexidine, such as brown 74 
discoloration of the teeth, alteration in taste, supragingival calculus formation and, more 75 
rarely, oral mucosal erosion and parotid swelling. Furthermore, this antiseptic is known to 76 
have a bitter taste [17–19]. In addition, some studies have reported a reduced efficacy of 77 
chlorhexidine in subgingival areas due to a low subgingival availability of the drug and the 78 
ability of P. gingivalis to release outer membrane vesicles that bind and inactivate 79 
chlorhexidine [20, 21]. Different classes of antibiotics have been used for the treatment of P. 80 
gingivalis-related infections, including tetracyclines (tetracycline hydrochloride, minocycline, 81 
doxycycline), macrolides (erythromycin), lincosamide (clindamycin), ß-lactams (ampicillin, 82 
amoxicillin) and nitroimidazoles (metronidazole) [14, 22, 23]. However, in recent years, the 83 
incidence of antibiotic-resistant oral bacteria such as P. gingivalis has increased  [24–27], 84 
highlighting the need for new antibacterials targeting oral infections.  85 
Recently, drug repurposing has emerged as a new strategy for the identification of new 86 
antibacterial agents [28]. As the safety and pharmacokinetic profiles of market drugs are 87 
already known, production time and costs are much lower in comparison with de novo 88 
discovery of antibiotics [28–30]. In an attempt to repurpose existing drugs as antibacterial 89 
agents, we recently screened the NIH clinical library against P. gingivalis [31]. One of the hit 90 
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compounds of the screening, AM404 (N-(4-hydroxyphenyl)-arachidonylamide), an active 91 
metabolite of paracetamol, was further characterized in this study.  92 
The first purpose of this study was to assess the antibacterial and antibiofilm activity of 93 
AM404 against P. gingivalis and other pathogens. In addition, cytotoxicity of AM404 was 94 
tested against different human cell lines. Finally, the antibacterial mode of action of AM404 95 
was investigated.  96 
 97 
MATERIAL AND METHODS 98 
Bacterial strains and chemicals 99 
P. gingivalis ATCC 33277, Prevotella intermedia ATCC 49046, Fusobacterium nucleatum 100 
ATCC 49256, and Aggregatibacter actinomycetemcomitans ATCC 43718 were routinely 101 
grown on agar (Blood agar base no. 2, Sigma-Aldrich NV) supplemented with 5 % horse 102 
blood (Horse Blood Defibrinated, Oxoid NV), hemin (5 µg/ml) (Sigma) and menadione (1 103 
µg/ml) (Sigma) at 37 °C under anaerobic conditions (90 % N2, 5 % H2, and 5 % CO2) using 104 
an Anoxomat AN2OP system (Mart Microbiology, Drachten, the Netherlands). Streptococcus 105 
mutans ATCC 25175, Staphylococcus aureus SH1000 [32], Staphylococcus epidermidis CH 106 
[33], Escherichia coli TG1 [34], Pseudomonas aeruginosa [35], and Salmonella enterica 107 
serovar Typhimurium SL1344 [36] were grown routinely on solid trypticase soy broth (TSB, 108 
Becton Dickinson Benelux) containing 1.5 % agar at 37 °C. AM404, arvanil, 4’-109 
hydroxystearanilde, and R(+)-methanandamide were purchased from Sigma-Aldrich and 110 
stock solutions of 20 mM were prepared in dimethyl sulfoxide (DMSO).  111 
 112 
Antibacterial assays 113 
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The minimal inhibitory concentration (MIC) of AM404 and its analogs were evaluated in 114 
TSB as described before [37]. To determine the minimal bactericidal concentration (MBC), 115 
10 µl aliquots were taken from the wells of the MIC assay that did not show bacterial growth 116 
and were plated onto blood agar plates. After incubation of the plates, the MBC was 117 
determined as the lowest concentration of AM404 for which CFUs were observed. 118 
 119 
Antibiofilm assays 120 
The ability of AM404 to inhibit biofilm formation of P. gingivalis was determined using the 121 
Calgary Biofilm Device (Nunc-Immuno TSP, VWR International) as described previously, 122 
with some modifications [38]. A bacterial suspension was prepared by diluting an overnight 123 
culture of P. gingivalis 1/10 in TSB. Two-fold serial dilutions of AM404 in bacterial 124 
suspension (150 µl) were prepared in the wells of 96-well microtiter plates. Thereafter, the 125 
peg lid of the Calgary Biofilm Device was placed on top of the microtiter plate and the 126 
biofilms were allowed to grow on the pegs for 72 h at 37 °C, without shaking. For 127 
quantification of biofilm formation, biofilms were stained with 0.1 % crystal violet as 128 
described previously [38]. The minimum biofilm inhibitory concentration (MBIC) value was 129 
determined as the lowest concentration of AM404 required to inhibit biofilm formation. 130 
To test the activity of AM404 against preformed P. gingivalis biofilms, 3-day-old biofilms 131 
were grown on peg lids as described above, and were subsequently treated with 150 µl TSB 132 
containing AM404 (0 - 200 µM) for 24 h at 37 °C. Next, pegs were washed with phosphate-133 
buffered saline (PBS) and the biofilms on the pegs were quantified by cell titre blue (CTB). 134 
Briefly, the peg lid was placed in a microtiter plate containing 200 µl of CTB diluted 1/100 in 135 
PBS. After 24 h of incubation in the dark at 37 °C, fluorescence was measured (λex: 535 nm 136 
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and λem: 590 nm) using the Synergy MX multimode reader (Biotek, Winooski, VT). The 137 
minimum biofilm reduction concentration (MBRC) was defined as the lowest concentration 138 
of AM404 able to kill bacteria growing in a biofilm.  139 
 140 
Inhibition of biofilm formation on titanium disks by AM404 141 
P. gingivalis biofilms were cultured on round titanium disks (commercially pure titanium, 142 
grade 2; height: 2 mm, width: 0.5 cm). Briefly, the disks were placed on the bottom of the 143 
wells of a 96-well microtiter plate and were covered with 200 µl of a 1/10 diluted overnight 144 
culture containing 0 to 12.5 µM AM404. After 72 h of incubation at 37 °C under static 145 
conditions, the disks were washed with PBS to remove non-adherent bacteria and were 146 
transferred to centrifuge tubes containing 1 mL PBS. Next, the disks were sonicated (45,000 147 
Hz in a water bath sonicator (VWR USC 300-T) for 10 min) and vortexed (1 min) to remove 148 
the bacteria from the disks. Serial dilutions of this bacterial solution were made and colony-149 
forming units (CFUs) were determined by plating serial-dilutions aliquots onto blood agar 150 
plates.  151 
 152 
Activity of AM404 against established biofilms formed on titanium disks 153 
To assess the ability of AM404 to disrupt preformed biofilms of P. gingivalis on titanium 154 
disks, 3-day-old biofilms were grown on the disks as described above. Thereafter, the disks 155 
were washed with PBS and were incubated with 200 µl of fresh TSB medium containing 0 to 156 
50 µM AM404 for an additional 24 h. Biofilm viability was quantified by CFU counts as 157 
described above.  158 
 159 
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Assessment of the viability of biofilms formed on titanium disks 160 
The BacLight LIVE/DEAD bacterial viability staining kit (Molecular Probes, Invitrogen) was 161 
used to microscopically evaluate the viability of the biofilms formed on titanium disks. After 162 
incubation, the disks were washed with 1x PBS and were transferred to a LIVE/DEAD 163 
staining solution containing SYTO 9 and propidium iodide (PI) (prepared according to 164 
manufacturer’s instructions). After 10 min of incubation at room temperature in the dark, the 165 
disks were washed again in 1x PBS and were mounted on a coverslip for imaging. The 166 
stained biofilm cells were visualized under a Zeiss Axio imager Z1 fluorescence microscope 167 
equipped with a EC Plan-Neofluar 20x objective using the SYTO 9 (λex = 483 nm; λem = 500 168 
nm) and PI (λex = 535 nm; λem = 617 nm) channels.  169 
 170 
Cytotoxicity assays 171 
HEK-293 (human embryonic kidney cells), HepG2 (human hepatoma cells), IEC-6 (rat 172 
intestinal cells), and Panc-1 cells (pancreatic cancer cells) were purchased from ATCC 173 
(Rockville, MD, USA). These cell lines were chosen as they are extensively used in in vitro 174 
toxicity assays.  Panc-1 cells were cultured in DMEM (Dulbecco’s Modified Eagle Medium), 175 
HEK-293 and HepG2 in MEM (Minimal Essential Medium), and IEC-6 cells in RPMI 1460 176 
medium. All culture media were purchased form Life Technologies (Carlsbad, USA) and 177 
supplemented with 10 % fetal calf serum, 2 mM L-glutamine, 100 U/mL penicillin, and 100 178 
µg/mL streptomycin, except for the RPMI medium, to which no L-glutamine was added. Cell 179 
lines were cultured using standard cell culture techniques (37 °C, 5 % CO2, 95 % humidity). 180 
Drug cytotoxicity testing was performed as described [39]. Briefly, following seeding, cells 181 
were treated for 24 h with a control (1 % DMSO) or a compound (0 - 253 µM). Subsequently, 182 
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cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 183 
bromide (MTT) and expressed relative to the control treatment. The results were expressed as 184 
cytotoxic concentrations that induce 50 % reduction in cell viability (CC50). 185 
 186 
Membrane permeabilization assays 187 
The ability of AM404 to permeabilize the outer and inner membranes of P. gingivalis was 188 
determined as previously described [40], using the fluorescent dyes N-phenyl-1-napthylamine 189 
(NPN, Sigma, USA) and SYTOX green (Invitrogen, USA), respectively. 1x the MIC of 190 
compound SPI031 (12.5 µM) was used as a positive control for outer membrane 191 
permeabilization because of its strong membrane permeabilizing properties [40]. 10 µg/ml 192 
melittin (MEL) was used a positive control for inner membrane permeabilization [41]. 193 
 194 
Fluorescence microscopy 195 
To visualize membrane damage induced by AM404, the membrane dye N-(3-196 
triethylammoniumpropyl)-4-(p-diethylaminophenyl-hexatrienyl) pyridinium dibromide (FM 197 
4-64, Molecular Probes) was used. Briefly, exponential-phase cells of P. gingivalis were 198 
incubated with DMSO (control) or 2x the MIC of AM404 for 30 min at 37 °C. Cells treated 199 
with 2x the MIC of triclosan (69.1 µM) were used as positive control. Cells treated with 2x 200 
the MIC of ciprofloxacin (1.9 µM), rifampicin (0.1 µM), and tetracycline (2.8 µM) were used 201 
as a negative control. Next, cells were collected by centrifugation and were stained with 10 202 
µg/ml FM 4-64 for 10 min at room temperature. Cells were visualized using a Zeiss Axio 203 
imager Z1 fluorescence microscope equipped with a EC Plan-Neofluar 100x objective, using 204 
the FM 4-64 channel (λex = 506 nm; λem = 751 nm). 205 
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 206 
Statistical analysis and reproducibility of the results 207 
Statistical analysis was performed by one-way ANOVA, followed by Dunnett's multiple 208 
comparison test. p-values < 0.001, < 0.01, and < 0.05 were considered to be statistically 209 
significant. All bacterial experiments were repeated at least three times. The cytotoxicity 210 
assay were performed in quadruplicate with four biological repeats. 211 
 212 
RESULTS 213 
AM404 shows antibacterial and antibiofilm activity against P. gingivalis 214 
Previously, we screened the NIH repurposing library to identify new antibacterial compounds 215 
with activity against P. gingivalis [31]. From this screening, three compounds were selected 216 
for further analysis: toremifene, zafirlukast, and AM404, which was further characterized in 217 
this study. In a first step, the activity of AM404 against different clinically important oral (P. 218 
gingivalis, S. mutans, P. intermedia, F. nucleatum, and A. actinomycetemcomitans) and non-219 
oral pathogens (S. aureus, S. epidermidis, E. coli, P. aeruginosa, and S. Typhimurium) was 220 
evaluated. AM404 showed potent antibacterial activity against P. gingivalis, with a MIC and 221 
MBC value of 12.5 µM. AM404 showed slightly less activity compared to the antiseptic 222 
chlorhexidine (MIC = 6.4 µM). The compound was not active against all other pathogens 223 
examined (MIC and BIC > 100 µM). In addition, AM404 was effective against P. gingivalis 224 
biofilms grown on polystyrene pegs with MBIC and MBRC values of 12.5 µM. Next, a small-225 
scale structure-activity analysis was conducted including three analogs of AM404 to 226 
determine molecular components important for antibacterial activity (Table 1). This revealed 227 
that the unsaturated carbon chain may be crucial for activity of AM404, as evidenced by the 228 
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inactivity of 4’-hydroxystearanilide (MIC > 200µM). Furthermore, removal of the phenol 229 
group (R(+)-methanandamide) or addition of a methoxy group to the phenol-group (arvanil) 230 
led to a reduced antibacterial efficacy (MIC of 50 and 25 µM, respectively).   231 
 232 
AM404 is active against P. gingivalis biofilms grown on titanium disks 233 
Titanium is commonly used as an implant material for dental implants, as it has a high level 234 
of biocompatibility [43]. Therefore we tested AM404’s activity against P. gingivalis biofilms 235 
grown on titanium disks. As shown in Fig. 1A, the compound completely inhibits biofilm 236 
formation on titanium disks at a concentration of 12.5 µM. In addition, AM404 significantly 237 
reduces the number of CFUs in biofilms formed on these surfaces in a concentration-238 
dependent manner (Fig. 1C). These results were further confirmed by LIVE/DEAD staining 239 
(Fig. 1B and 1D). In the control treatment, green viable cells were predominant compared to 240 
the red dead cells. Treatment with AM404 resulted in a significant reduction of green cells. 241 
Only few red-stained cells were observed after treatment, indicating that AM404 is able to 242 
fully clear established biofilms from surfaces. 243 
 244 
AM404 displays limited cytotoxicity 245 
The cytotoxicity of AM404 was evaluated against HEK-293 (human embryonic kidney cells), 246 
HepG2 (human hepatoma cells), IEC-6 (rat intestinal cells), and Panc-1 cells (pancreatic 247 
cancer cells). As shown in Table 2, CC50 values for HEK-293, HepG2, IEC-6 and Panc-1 cells 248 
are 67.77 ± 12.07, 42.16 ± 7.40, 73.29 ± 8.04, and 67.84 ± 5.91, respectively. These results 249 
show that AM404 is not toxic up to concentrations approaching 4x the MIC of AM404. 250 
 251 
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AM404 permeabilizes the inner and outer membrane of P. gingivalis 252 
To assess the mode of action of AM404 on the bacterial outer membrane, the hydrophobic 253 
fluorescent probe NPN was used. Under normal circumstances, NPN is excluded from the 254 
outer membrane. However, when the outer membrane is damaged, NPN can partition into the 255 
outer membrane which results in increased fluorescence [44]. As shown in Fig. 2A, treatment 256 
of P. gingivalis cells with AM404 rapidly permeabilizes the outer membrane in a 257 
concentration-dependent manner as observed by an increase in fluorescence. The nucleic acid 258 
stain SYTOX green was used to evaluate permeabilization of the inner membrane of P. 259 
gingivalis by AM404. SYTOX green is excluded from cells with intact inner membranes. 260 
However, when the inner membrane is disrupted, SYTOX green can enter the cytoplasm and 261 
bind with nucleic acids, which results in an increase in fluorescence [45]. As shown in Fig. 262 
2B, treatment with AM404 rapidly disrupts the integrity of the inner membrane in a 263 
concentration-dependent manner. Outer and inner membrane permeabilization was induced 264 
by 1x the MIC of AM404 to the same extent as the positive controls SPI031 and melittin, 265 
respectively.  266 
 267 
Microscopic visualization of membrane damage 268 
Disruption of membrane integrity by AM404 was further confirmed microscopically using the 269 
fluorescent membrane stain FM 4-64 (Fig. 3). Treatment with AM404 at 2x the MIC for 30 270 
min results in non-homogeneously stained membranes with clear membrane accumulations. 271 
Non-homogeneously stained membranes are also observed after treatment of the cells with 2x 272 
the MIC of the membrane-damaging antibiotic triclosan as a positive control. No such 273 
phenotype is observed after treatment of the cells with antibiotics with other modes of actions 274 
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(ciprofloxacin (DNA synthesis), rifampicin (RNA synthesis), and tetracycline (protein 275 
synthesis) (Fig. S1)).  276 
 277 
DISCUSSION 278 
We demonstrated that AM404 shows strong antibacterial activity against P. gingivalis, with 279 
MIC, MBC, MBIC and MBRC values of 12.5 µM. Strikingly, the activity of AM404 against 280 
planktonic and biofilm cultures appears to be similar, underlining the antibacterial potential of 281 
this compound. Thus, the biofilm lifestyle, including the presence of an extracellular matrix 282 
did not affected the activity of AM404. No activity was found against other clinically 283 
important oral (S. mutans, P. intermedia, F. nucleatum, and A. actinomycetemcomitans) and 284 
non-oral pathogens (S. aureus, S. epidermidis, E. coli, P. aeruginosa, and S. Typhimurium), 285 
suggesting that the compound displays species-specific activity. Future studies investigating 286 
the activity of AM404 against other strains of P. gingivalis can provide more clarity on this 287 
subject. A structure-activity analysis indicated that the unsaturated carbon chain may be 288 
essential for the compound’s activity against P. gingivalis. A more thorough structure-activity 289 
analysis may shed more light on this relationship and is likely to lead to the identification of 290 
even more active compounds. We also demonstrated that AM404 can inhibit biofilm 291 
formation as well as eradicate preformed biofilms of P. gingivalis on both polystyrene and 292 
titanium surfaces. The latter underlines the potential of AM404 as an agent that can be used in 293 
the prevention and treatment of peri-implantitis.  294 
In recent years, more and more research has focused on finding new antibacterial compounds 295 
targeting a specific organism, thereby reducing the effect on the commensal, resident flora. As 296 
for the oral cavity, different studies have published promising results on antimicrobial 297 
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peptides specifically designed to target S. mutans, a key pathogen involved in caries [46–48]. 298 
Furthermore, two studies have previously identified antibacterial peptides specifically 299 
targeting P. gingivalis [49, 50]. In addition to their therapeutic effect, target-specific 300 
antibacterials may be used as a tool to study the role of a particular pathogen in complex 301 
microbial communities such as biofilms found in the oral cavity [48, 51]. As such, in future 302 
research and in addition to studies validating the therapeutic effect of AM404, it would be 303 
interesting to use AM404 to further examine the role of P. gingivalis as a major pathogen in 304 
diseases such as periodontitis and peri-implantitis. Naturally, for this to work, the activity of 305 
AM404 against P. gingivalis should be first tested in a mixed biofilm setup.  306 
Several biological activities on eukaryotic cells have previously been reported for AM404, 307 
including activating the capsaicin receptor TRPV1, inhibiting COX, activating cannabinoid 308 
receptors, inhibiting cellular anandamide reuptake and inhibiting NFAT activity and IkB 309 
kinase beta phosphorylation and activation [52–56]. A recent study also identified AM404 as 310 
an antiviral agent that effectively inhibits replication of the Dengue virus by binding with the 311 
NS4B protein [57]. To our knowledge, no studies exist on the antibacterial activities of 312 
AM404 and its mode of action. In a first attempt to elucidate the antibacterial mode of action 313 
of AM404, its effect on the membrane of P. gingivalis was investigated. Interestingly, 314 
AM404 rapidly permeabilizes both outer and inner membranes, as evidenced by increased 315 
influx of NPN and SYTOX green into the cells. To visualize membrane damage caused by 316 
AM404, fluorescence microscopy images were obtained of P. gingivalis cells after treatment 317 
with AM404. Specific membrane accumulations were observed after treatment as compared 318 
to untreated cells. Similar accumulations were seen after treatment of the cells with the known 319 
membrane-damaging agent triclosan. P. gingivalis is known to have atypical membrane 320 
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structures as it possesses unique lipid A moieties that exhibit structural heterogeneity [58]. 321 
This aberrant lipid A also explains its resistance to polymyxin B, a membrane-damaging 322 
agent frequently used as a last-resort antibiotic for treatment of infections caused by Gram-323 
negative bacteria [58, 59]. We therefore hypothesize that the selective activity of AM404 may 324 
be due to its specific binding to specific membrane structures of P. gingivalis, presumably via 325 
its highly hydrophobic carbon chain. In the future, additional tests should be performed to 326 
fully understand the molecular mechanisms behind the observed membrane damage.  327 
In summary, we found that AM404 displays specific antibacterial and antibiofilm activity 328 
against P. gingivalis, presumably by damaging the membrane. To our knowledge, this is the 329 
first report of a non-peptide antibacterial agent specifically targeting P. gingivalis. Peptide-330 
based antibacterial agents have some disadvantages such as high production costs, limited 331 
stability, and unknown toxicology [60], making AM404 a promising candidate for 332 
development of therapies targeting P. gingivalis. In future studies, it may be worth 333 
investigating the activity of AM404 against major virulence determinants of P. gingivalis as 334 
this is central to the pathogen’s activity. In addition, the toxicity of AM404 against oral cell 335 
lines and its activity under in vivo conditions needs to be tested to fully establish its clinical 336 
importance. As AM404 is partly or fully responsible for the analgesic activity of paracetamol, 337 
this compound could be administered as a drug with a dual action, both reducing bacterial 338 
load and inflammatory pains associated with periodontal diseases [52, 53, 61]. Our findings 339 
together with the low cytotoxicity of the compound (Table 2), highlight the potency of this 340 
drug to be used for the development of new therapeutics for treatment of periodontitis and 341 
peri-implantitis.   342 
 343 
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 513 
 514 
TABLES 515 
 516 
Table 1. MIC values of structural analogs of AM404* 517 
Compound Structure MIC (µM) 
AM404 
 
12.5 
arvanil 
 
25 
   
R(+)-methanandamide 
 
50 
4’-hydroxystearanilide 
 
> 200 
22 
 
*Abbreviations: MIC, minimum inhibitory concentration 518 
 519 
Table 2. Mean CC50 values ± SEM of AM404 against HEK-293, HepG2, IEC-6, and Panc-1 520 
cells (n = 4)* 521 
 522 
 523 
 524 
 525 
 526 
*Abbreviations: CC50, cytotoxic concentration that induces 50 % reduction in cell viability; 527 
SD, standard deviation 528 
 529 
FIGURES 530 
 531 
Figure 1. Effect of AM404 on P. gingivalis biofilms formed on titanium disks. (A) Reduction 532 
of P. gingivalis biofilm formation in the presence of AM404, as determined by CFU counts. 533 
(B) Reduction of P. gingivalis biofilm formation in the presence of AM404, as determined by 534 
LIVE/DEAD staining. (C) Eradication of preformed biofilms of P. gingivalis by AM404, as 535 
determined by CFU counts. (C) Eradication of preformed biofilms of P. gingivalis by 536 
AM404, as determined by LIVE/DEAD staining. In A and C, values are means ± SEM of 537 
three independent experiments. ***p < 0.001 as compared to the untreated control. In B and 538 
D, scale bars correspond to 100 µm. Images were processed with unsharp mask of Zen 2.0.  539 
 540 
 CC50 (µM) 
HEK-293 67.77 ± 12.07 
HEPG2 42.16 ± 7.40 
IEC-6 73.29 ± 8.04 
Panc-1 67.84 ± 5.91 
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Figure 2. Effect of AM404 on outer (A) and inner (B) membrane permeabilization of P. 541 
gingivalis, as assessed by NPN and SYTOX green uptake, respectively. 1x the MIC of 542 
SPI031 was used as a positive control for outer membrane permeabilization [40]. 10 µg/ml 543 
melittin (MEL) was used a positive control for inner membrane permeabilization [41]. Data 544 
represent the means of three independent replicates ± SEM (*p < 0.05, **p < 0.01, ***p < 545 
0.001). 546 
 547 
Figure 3. Visualization of antibiotic-induced membrane damage using the fluorescent 548 
membrane dye FM 4-64. Fluorescent images of P. gingivalis cells after treatment for 30 min 549 
with DMSO (solvent control), 2x the MIC of AM404, and 2x the MIC of triclosan (TRI). 550 
Scale bars correspond to 2 µm. Images were processed with unsharp mask of Zen 2.0. 551 
 552 
Figure S1. Fluorescence microscopy images of P. gingivalis cells stained with FM4-64 after 553 
treatment with 2x the MIC of ciprofloxacin (CIP), rifampicin (RIF), and tetracycline (TET). 554 
Scale bars correspond to 2 µm. Images were processed with unsharp mask of Zen 2.0. 555 
